Stock futures dipped and bond yields moved higher on Thursday as recent hopes over a summer rate cut were pared somewhat. Markets are pricing in a 91.3% probability that the Fed will leave interest ...

Biogen BIIB is having a tough year: Its shares are down 15% through early May. The wide-moat drugmaker’s new product launches ...

Following our review of Occidental Petroleum’s OXY first-quarter results, we’ve reduced our fair value estimate by 7% to $53 ...

We’ve raised our fair value estimate for Apple to $170 per share from $160 due to higher expectations for iPhone revenue in ...

Takeda Pharmaceutical reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses. The Japanese drugmaker said Thursday that it booked a net loss of ...

Takeda Pharmaceutical reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses. The Japanese drugmaker said Thursday that it booked a net loss of ...

U.K. interest rate decision; trading updates from Enel, Pirelli, Telefonica, Salvatore Ferragamo, Airtel Africa, 3i Group, Wood Group, ITV Opening Call: European stock futures were higher despite a ...

BAE Systems confirmed its forecasts that sales and earnings will continue to grow this year as governments rush to secure military hardware in the face of escalating geopolitical tensions. The U.K.

SYDNEY--Commonwealth Bank of Australia posted a fall in third-quarter profit, reporting slightly lower margins as competition remains in the country's retail banking sector. The bank, Australia's ...

SYDNEY--Commonwealth Bank of Australia posted a fall in third-quarter profit, reporting slightly lower margins as competition remains in the country's retail banking sector. The bank, Australia's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.